ReviewCurrent hypertension reports2023
Gut Microbiota and Its Role in the Brain-Gut-Kidney Axis in Hypertension.
Review in Current hypertension reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Analysis of Gut Microbiota Metabolites in Chronic Kidney Disease-Associated Pruritus Using Network Pharmacology and Molecular Docking.Iranian journal of biotechnology · 2026Article
- Review
- Investigation of Transcriptome and Kinome in Non Metastatic and Metastatic Renal Clear Cancer Stem Cells and Their Relationship with Gut Microbiota.Molecular biotechnology · 2026Article
- Ultra-Processed Foods and Chronic Kidney Disease: Is Inflammaging the Missing Link?Biomolecules · 2026Review
- Obesity and Its Clinical Implications in End-Stage Kidney Disease.Medicina (Kaunas, Lithuania) · 2026Review
- Rethinking Celiac Disease Management: Treatment Approaches Beyond the Gluten-Free Diet.Biomedicines · 2025Review
- Decoding the Spectrum of Anorexia Nervosa: Clinical Impact, Molecular Insights, and Therapeutic Perspectives.Biomolecules · 2025Review
- Food as Medicine for Hypertension: Microbiota as Mediators.Hypertension (Dallas, Tex. : 1979) · 2025Review
- Bacterial Extracellular Vesicles: Emerging Regulators in the Gut-Organ Axis and Prospective Biomedical Applications.Current microbiology · 2025Review
- Article
- Gut Microbiota and Their Metabolites: The Hidden Driver of Diabetic Nephropathy? Unveiling Gut Microbe's Role in DN.Journal of diabetes · 2025Review
- Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment.Diagnostics (Basel, Switzerland) · 2025Review
- The influence of gut microbiota on the gut-brain-kidney axis and its implications for chronic kidney disease.Frontiers in microbiology · 2025Review
- The critical role of Th17 cells and IL-17A in autoimmune and inflammation-associated neurological diseases: mechanisms and therapeutic perspectives.Frontiers in immunology · 2025Review
- The Kidney in Obesity: Current Evidence, Perspectives and Controversies.Current obesity reports · 2024Review
- Diet patterns, gut microbiota and metabolic disorders: Perspectives and challenges.Metabolism open · 2024Article
- The Interplay Between Dietary Choline and Cardiometabolic Disorders: A Review of Current Evidence.Current nutrition reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe role of the gut microbiota in modulating blood pressure is increasingly being recognized, currently. The purpose of this review is to summarize recent findings about the mechanisms involved in hypertension with regard to the phenomenon of "gut dysbiosis." RECENT
findingsGut dysbiosis, i.e., the imbalance between the gut microbiota and the host, is characterized by a disruption of the tight junction proteins, such as occludins, claudins, and JAMs (junctional adhesion molecules), resulting in increased gut permeability or the so called "leaky gut." Due to the influence of genetic as well as environmental factors, various metabolites produced by the gut microbiota, such as indole and p-cresol, are increased. Thereby, uremic toxins, such as indoxyl sulfates and p-cresol sulfates, accumulate in the blood and the urine, causing damage in the podocytes and the tubular cells. In addition, immunological mechanisms are implicated as well. In particular, a switch from M2 macrophages to M1 macrophages, which produce pro-inflammatory cytokines, occurs. Moreover, a higher level of Th17 cells, releasing large amounts of interleukin-17 (IL-17), has been reported, when a diet rich in salt is consumed. Therefore, apart from the aggravation of uremic toxins, which may account for direct harmful effects on the kidney, there is inflammation not only in the gut, but in the kidneys as well. This crosstalk between the gut and the kidney is suggested to play a crucial role in hypertension. Notably, the brain is also implicated, with an increasing sympathetic output. The brain-gut-kidney axis seems to be deeply involved in the development of hypertension and chronic kidney disease (CKD). The notion that, by modulating the gut microbiota, we could regulate blood pressure is strongly supported by the current evidence. A healthy diet, low in animal protein and fat, and low in salt, together with the utilization of probiotics, prebiotics, synbiotics, or postbiotics, may contribute to our fight against hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.